Literature DB >> 34313922

LINC00667 Promotes Progression of Esophageal Cancer Cells by Regulating miR-200b-3p/SLC2A3 Axis.

Jindun Pan1, Yunhong Zang2.   

Abstract

BACKGROUND: Recently, more and more evidence indicated that the long non-coding RNA was strictly related to the occurrence and progression of human cancers, including esophageal cancer (EC). We observed that LINC00667 was increased in EC, but the function of LINC00667 was unclear. Therefore, the function and potential molecular mechanism of LINC00667 in the progression of EC need to be further studied.
METHODS: Quantitative real-time PCR was used to investigate the levels of LINC00667, miR-200b-3p, and SLC2A3. The levels of protein involved in cell cycle, cell apoptosis, epithelial-mesenchymal transition, as well as SLC2A3 were quantitatived by western blot. The role of LINC00667 in the proliferative, migratory and invasive capabilities of EC cells were measured by cell counting kit-8 assay, EdU assay, flow cytometry assay, wound healing assay and transwell assay, respectively. Interaction between LINC00667 and miR-200b-3p or miR-200b-3p and SLC2A3 were confirmed using a luciferase reporter assay.
RESULTS: In this work, we found that LINC00667 expression was up-regulated in EC cell lines, and LINC00667 knockdown inhibited cell proliferation, migration, and invasion in EC cells. In addition, it showed that LINC00667 functioned as competitive endogenous RNA for miR-200b-3p by the DIANA-LncBase database. Moreover, we used targetscan online software to predict SLC2A3 as a target gene of miR-200b-3p. Subsequently, rescue experiments confirmed that knocking out SLC2A3 could reverse the inhibitory effect of miR-200b-3p on EC cells transfected with sh-LINC00667.
CONCLUSION: Herein, we revealed the novel mechanism of LINC00667 on regulating metastasis-related gene by sponge regulatory axis during EC metastasis. Our results demonstrated that LINC00667 plays a critical role in metastatic EC by mediating sponge regulatory axis miR-200b-3p/SLC2A3. To explore function of LINC00667/miR-200b-3p/SLC2A3 axis may provide an informative biomarker of malignancy and a highly selective anti-EC therapeutic target.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Epithelial–mesenchymal transition; Esophageal cancer; SLC2A3; lncRNA; miR-200b-3p

Mesh:

Substances:

Year:  2021        PMID: 34313922     DOI: 10.1007/s10620-021-07145-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  29 in total

1.  LncRNA and mRNA integration network reconstruction reveals novel key regulators in esophageal squamous-cell carcinoma.

Authors:  Shervin Alaei; Balal Sadeghi; Ali Najafi; Ali Masoudi-Nejad
Journal:  Genomics       Date:  2018-01-06       Impact factor: 5.736

2.  Molecular basis of ligand recognition and transport by glucose transporters.

Authors:  Dong Deng; Pengcheng Sun; Chuangye Yan; Meng Ke; Xin Jiang; Lei Xiong; Wenlin Ren; Kunio Hirata; Masaki Yamamoto; Shilong Fan; Nieng Yan
Journal:  Nature       Date:  2015-07-15       Impact factor: 49.962

3.  LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis.

Authors:  Jie Chu; Hongle Li; Yurong Xing; Jinlin Jia; Jinxiu Sheng; Lijun Yang; Kaiyan Sun; Yunhui Qu; Yan Zhang; Huiqing Yin; Junhu Wan; Fucheng He
Journal:  Biomed Pharmacother       Date:  2019-06-03       Impact factor: 6.529

4.  LncRNA H19 promotes epithelial mesenchymal transition and metastasis of esophageal cancer via STAT3/EZH2 axis.

Authors:  Ming-Jiu Chen; Jie Deng; Chen Chen; Wen Hu; Yun-Chang Yuan; Zhen-Kun Xia
Journal:  Int J Biochem Cell Biol       Date:  2019-05-16       Impact factor: 5.085

Review 5.  LncRNAs Coming of Age.

Authors:  Phillip Grote; Reinier A Boon
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

Review 6.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.

Authors:  María José Domper Arnal; Ángel Ferrández Arenas; Ángel Lanas Arbeloa
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

7.  Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics.

Authors:  J Chen; D L Kwong; T Cao; Q Hu; L Zhang; X Ming; J Chen; L Fu; X Guan
Journal:  Dis Esophagus       Date:  2013-06-24       Impact factor: 3.429

Review 8.  Screening for esophageal squamous cell carcinoma: recent advances.

Authors:  Don C Codipilly; Yi Qin; Sanford M Dawsey; John Kisiel; Mark Topazian; David Ahlquist; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2018-04-27       Impact factor: 9.427

Review 9.  Glucose transporters in cancer - from tumor cells to the tumor microenvironment.

Authors:  Pierre-Benoit Ancey; Caroline Contat; Etienne Meylan
Journal:  FEBS J       Date:  2018-06-25       Impact factor: 5.542

10.  MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells.

Authors:  Di Chen; Hui Wang; Jie Chen; Zhe Li; Shengli Li; Zhixiang Hu; Shenglin Huang; Yingjun Zhao; Xianghuo He
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more
  3 in total

1.  LncRNA LINC00667 aggravates the progression of hepatocellular carcinoma by regulating androgen receptor expression as a miRNA-130a-3p sponge.

Authors:  Zhixiang Qin; Xiaohong Liu; Zijing Li; Ganggang Wang; Zhe Feng; Ye Liu; Hai Yang; Chengpeng Tan; Zidong Zhang; Kun Li
Journal:  Cell Death Discov       Date:  2021-12-14

2.  Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma.

Authors:  Xu-Sheng Liu; Xue-Yan Kui; Yan Gao; Xue-Qin Chen; Jing Zeng; Xiao-Yu Liu; Yu Zhang; Yao-Hua Zhang; Zhi-Jun Pei
Journal:  Front Genet       Date:  2022-03-23       Impact factor: 4.599

Review 3.  Regulatory functions of miR‑200b‑3p in tumor development (Review).

Authors:  Sheng Chen; Yifeng Tu; Hang Yuan; Zhan Shi; Yang Guo; Wenjing Gong; Shiliang Tu
Journal:  Oncol Rep       Date:  2022-03-24       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.